Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

NCT02045212 is registered in ClinicalTrials.gov with Regenera Pharma Ltd as lead sponsor.

NCT NCT02045212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02045212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
Lead sponsor
Regenera Pharma Ltd
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
December 31, 2016
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-arteritic ischemic optic neuropathy, optic nerve injuries